Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 3/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20400683 | 1.00 | GRM2 (0.37) | GRM2GRM3DGAT1CTSSCTSK | |
| SCHEMBL2164713 | 1.00 | GRM2 (0.37) | GRM2GRM3DGAT1CTSSCTSK | |
| Water SCHEMBL27575288 | 0.98 | CTSS (0.37) | GRM2GRM3DGAT1CTSSCTSK | |
| Water SCHEMBL9292988 | 0.98 | CTSS (0.37) | GRM2GRM3DGAT1CTSSCTSK | |
| SCHEMBL28815008 | 0.84 | DGAT1 (0.47) | DGAT1CTSSCTSKCTSLCTSB | |
| SCHEMBL28775484 | 0.83 | CHRNB2 (0.34) | DGAT1 | |
| SCHEMBL27679361 | 0.80 | MMP8 (0.34) | DGAT1MMP8 | |
| SCHEMBL28721112 | 0.79 | DGAT1 (0.39) | DGAT1MEN1GAAKMT2A | |
| SCHEMBL4366519 | 0.79 | DGAT1 (0.39) | DGAT1MEN1GAAKMT2A | |
| SCHEMBL609386 | 0.79 | DGAT1 (0.39) | DGAT1MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851434-B2 | Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-12-26 | — | — | US | disclosed |
| EP-3571203-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220119396-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2022-04-21 | — | — | US | disclosed |
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC | 2020-02-20 | — | — | US | disclosed |
| WO-2018136661-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-07-26 | — | — | WO | disclosed |
| US-9029567-B2 | Hypoglycemic compounds | CADILA PHARMACEUTICALS LIMITED (IN) | 2015-05-12 | — | — | US | disclosed |
| EP-2769978-A1 | saxagliptin derivatives | Cadila Pharmaceuticals Limited (IN) | 2014-08-27 | — | — | EP | disclosed |
| US-20130150578-A1 | NOVEL HYPOGLYCEMIC COMPOUNDS | CADILA PHARMACEUTICALS LIMITED (IN) | 2013-06-13 | — | — | US | disclosed |
| CN-103119037-A | Phenyl quinazoline derivatives | MERCK PATENT GMBH | 2013-05-22 | — | — | CN | disclosed |
| WO-2011125011-A1 | NOVEL HYPOGLYCEMIC COMPOUNDS | CADILA PHARMACEUTICALS LIMITED (IN) | 2011-10-13 | — | — | WO | disclosed |
| CN-102143942-A | Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors | NOVARTIS AG | 2011-08-03 | — | — | CN | disclosed |
| CN-102007118-A | Pyrrolidinone glucokinase activators | HOFFMANN LA ROCHE | 2011-04-06 | — | — | CN | disclosed |
| CN-101896469-A | Substituted hydantoins as MEK kinase inhibitors | HOFFMANN LA ROCHE | 2010-11-24 | — | — | CN | disclosed |
| CN-101023079-B | Substituted hydantoins for the treatment of cancer | HOFFMANN LA ROCHE | 2010-05-05 | — | — | CN | disclosed |
| CN-101597284-A | A kind of preparation method of antineoplastic compound | BEIJING LAIDESAILUSEN PHARMACE (CN) | 2009-12-09 | — | — | CN | disclosed |
| CN-101389609-A | Hydantoin-based kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2009-03-18 | — | — | CN | disclosed |
| CN-101023079-A | Substituted hydantoins for the treatment of cancer | HOFFMANN LA ROCHE (CH) | 2007-08-22 | — | — | CN | disclosed |
| CN-1780821-A | Heterocyclic kinase inhibitors. | ABBOTT LAB (US) | 2006-05-31 | — | — | CN | disclosed |
| CN-1362947-A | N-cyanomethylamides as protease inhibitors | AXYS PHARM INC (US) | 2002-08-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119396-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, ROR1 | GRM2 880/4885GRM3 608/4885DGAT1 4832/4885 |
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, ROR1 | GRM2 880/4885GRM3 608/4885DGAT1 4832/4885 |
| US-11851434-B2 | Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors | RET, BRAF, ROR1 | GRM2 880/4885GRM3 608/4885DGAT1 4832/4885 |
| US-20130150578-A1 | NOVEL HYPOGLYCEMIC COMPOUNDS | GLP1R, GPR119, IAPP | GRM2 2447/4885GRM3 2419/4885DGAT1 622/4885 |
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | RET, BRAF, ROR1 | GRM2 850/4885GRM3 591/4885DGAT1 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.